ArticleThe Biochemical journal1996
Immunological characterization of eristostatin and echistatin binding sites on alpha IIb beta 3 and alpha V beta 3 integrins.
Article in The Biochemical journal, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 54 citations in OpenAlex.
- Exogenous Integrin αIIbβ3 Inhibitors Revisited: Past, Present and Future Applications.International journal of molecular sciences · 2021Review
- Influence of integrins on thrombus formation: a road leading to the unravelling of DVT.Molecular and cellular biochemistry · 2021Review
- The antitumor efficacy of monomeric disintegrin obtustatin in S-180 sarcoma mouse model.Investigational new drugs · 2019Article
- Association of p75(NTR) and α9β1 integrin modulates NGF-dependent cellular responses.Cellular signalling · 2015Article
- CCN2 suppresses catabolic effects of interleukin-1β through α5β1 and αVβ3 integrins in nucleus pulposus cells: implications in intervertebral disc degeneration.The Journal of biological chemistry · 2014Article
- Enhanced reseeding of decellularized rodent lungs with mouse embryonic stem cells.Biomaterials · 2014Article
- Applications of snake venom components to modulate integrin activities in cell-matrix interactions.The international journal of biochemistry & cell biology · 2013Review
- Mechanical loading promotes mast cell degranulation via RGD-integrin dependent pathways.Journal of biomechanics · 2013Article
- Importance of interaction between nerve growth factor and α9β1 integrin in glial tumor angiogenesis.Neuro-oncology · 2012Article
- Integrins mediate adhesion of medulloblastoma cells to tenascin and activate pathways associated with survival and proliferation.Laboratory investigation; a journal of technical methods and pathology · 2008Article
- Angiostatic activity of obtustatin as alpha1beta1 integrin inhibitor in experimental melanoma growth.International journal of cancer · 2008Article
- Integrin alpha9 beta1 is a receptor for nerve growth factor and other neurotrophins.Journal of cell science · 2008Article
- Interaction between serine phosphorylated IRS-1 and beta1-integrin affects the stability of neuronal processes.Journal of neuroscience research · 2007Article
- Fibronectin-mediated upregulation of α5β1 integrin and cell adhesion during differentiation of mouse embryonic stem cells.Cell adhesion & migrationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
Two disintegrins with a high degree of amino acid sequence similarity, echistatin and eristostatin, showed a low level of interaction with Chinese hamster ovary (CHO) cells, but they bound to CHO cells transfected with alpha IIb beta 3 genes (A5 cells) and to CHO cells transfected with alpha v beta 3 genes (VNRC3 cells) in a reversible and saturable manner. Scatchard analysis revealed that eristostatin bound to 816000 sites per A5 cell (Kd 28 nM) and to 200000 sites (Kd 14 nM) per VNRC3 cell respectively. However, VNRC3 cells did not bind to immobilized eristostatin. Echistatin bound to 495000 sites (Kd 53 nM) per A5 cell and to 443000 sites (Kd 20 nM) per VNRC3 cell. As determined by flow cytometry, radiobinding assay and adhesion studies, binding of both disintegrins to A5 cells and resting platelets and binding of echistatin to VNRC3 cells resulted in the expression of ligand-induced binding sites (LIBS) on the beta 3 subunit. Eristostatin inhibited, more strongly than echistatin, the binding of three monoclonal antibodies: OPG2 (RGD motif dependent), A2A9 (alpha IIb beta 3 complex dependent) and 7E3 (alpha IIb beta 3 and alpha v beta 3 complex dependent) to A5 cells, to resting and to activated platelets and to purified alpha IIb beta 3. Experiments in which echistatin and eristostatin were used alone or in combination to inhibit the binding of 7E3 and OPG2 antibodies to resting platelets suggested that these two disintegrins bind to different but overlapping sites on alpha IIb beta 3 integrin. Monoclonal antibody LM 609 and echistatin seemed to bind to different sites on alpha v beta 3 integrin. However, echistatin inhibited binding of 7E3 antibody to VNRC3 cells and to purified alpha v beta 3 suggesting that alpha v beta 3 and alpha IIb beta 3 might share the same epitope to which both echistatin and 7E3 bind. Eristostatin had no effect in these systems, providing further evidence that it binds to a different epitope on alpha v beta 3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.